{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-004819","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2022-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.064616+00:00","generated_at":"2026-06-24T19:32:17.294135+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M","bullets":["Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.","Catalent to provide manufacturing services for clinical supply to support planned Phase 1 study.","DNase platform targets NETs to enhance efficacy of immunotherapies and chemotherapies in solid tumors.","Initial indication focus includes pancreatic carcinoma, a multi-billion-dollar market.","CEO Jeffrey Eisenberg says this is an important step towards first-in-human studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-004819","json":"https://secwatch.observer/filing/0001683168-22-004819.json","markdown":"https://secwatch.observer/filing/0001683168-22-004819.md","text":"https://secwatch.observer/filing/0001683168-22-004819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/0001683168-22-004819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822004819/xenetic_8k-070622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T19:32:17.294135+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}